Ovarian cancer and homologous recombination deficiency
Clinical research is centered on advanced ovarian cancer, including stage III and stage IV disease, with attention to non-mucinous epithelial ovarian cancer and fallopian and peritoneal cancers. The studies also focus on tumors with HRD features and treatment after response to platinum-based chemotherapy.
- Maintenance therapy
- Neoadjuvant treatment
- HRD-positive ovarian cancer
- Platinum-sensitive disease
The portfolio includes work in both newly treated and recurrent settings, with emphasis on disease control in advanced ovarian malignancies.
Endometrial cancer and mismatch repair biomarkers
Another major area of interest is recurrent or primary advanced endometrial cancer, including populations defined by dMMR, MSI-H, MMRp, and MSS status. Research activity in this area reflects a focus on biomarker-linked treatment selection in advanced uterine cancer.
- Advanced endometrial cancer
- dMMR/MSI-H disease
- MMRp/MSS disease
- Recurrent uterine cancer
These studies examine treatment approaches for patients whose disease has returned or remains active after prior therapy.
PARP inhibitor-based oncology
The sponsor funds research involving niraparib, with attention to its role in ovarian cancer and endometrial cancer. The clinical program explores its use as a maintenance option and in combination settings across advanced gynecologic cancers.
- Niraparib
- Maintenance treatment
- Combination therapy
- Gynecologic oncology
This area links targeted cancer treatment with management of advanced disease following initial response or in earlier treatment lines.
Immuno-oncology and PD-1 pathway research
Clinical trials also include dostarlimab and other anti-PD-1 monoclonal antibodies, reflecting interest in immune checkpoint inhibition for gynecologic and broader solid tumor indications. These studies evaluate immune-based strategies in advanced cancers.
- Dostarlimab
- Anti-PD-1 therapy
- Immune checkpoint blockade
- Advanced solid tumors
Research extends across combination regimens and recurrent disease settings, especially in cancers with limited treatment options.
Advanced solid tumors
Beyond gynecologic malignancies, the sponsor supports studies in advanced solid tumors, including evaluation of TSR-042 and TSR-022 in patients with progressive cancer. This broad oncology interest includes tumors outside the ovarian and endometrial indications.
- Advanced solid tumors
- Monoclonal antibodies
- Oncology immunotherapy
- Multicohort cancer studies
The research landscape shows activity across multiple cancer types with an emphasis on difficult-to-treat advanced disease.
